- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.01. | NASDAQ: Delisting von Bolt Projects Holdings nach Nichterfüllung der Eigenkapitalanforderungen | 1 | Investing.com Deutsch | ||
| 05.01. | Bolt Projects Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 29.12.25 | Bolt Projects Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.11.25 | Bolt Projects Holdings GAAP EPS of -$2.70, revenue of $0.37M | 1 | Seeking Alpha | ||
| BOLT PROJECTS Aktie jetzt für 0€ handeln | |||||
| 12.11.25 | Bolt Projects Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.10.25 | Bolt Projects announces prelim Q3 results and updates 2025 guidance | 1 | Seeking Alpha | ||
| 17.10.25 | Bolt Projects Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.10.25 | Bolt Projects Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 26.09.25 | Bolt Projects registers 20M shares for potential sale under $20M equity line | 2 | Seeking Alpha | ||
| 26.09.25 | Bolt Projects Holdings, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 15.09.25 | Bolt Projects Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.08.25 | Bolt Projects Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.08.25 | Bolt Projects files to sell 913,979 shares of common stock for holders | 1 | Seeking Alpha | ||
| 22.08.25 | Bolt Projects Holdings, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 15.08.25 | Bolt Projects to raise $4.25M in private placement | 5 | Seeking Alpha | ||
| 15.08.25 | Bolt Projects announces $4.25 million private placement | 1 | Investing.com | ||
| 14.08.25 | Aktie von Bolt Projects bricht nach Kapitalerhöhung mit hohem Abschlag ein | 2 | Investing.com Deutsch | ||
| 14.08.25 | Bolt Projects stock tumbles after discounted share offering | 12 | Investing.com | ||
| 14.08.25 | Pre-market Movers: Sonoma Pharmaceuticals, Bolt Projects, Ibotta, TeraWulf, 180 Life Sciences | 803 | AFX News | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.50 A.M. ET).In the Green Sonoma Pharmaceuticals, Inc. (SNOA) is up over... ► Artikel lesen | |
| 14.08.25 | Bolt Projects Holdings, Inc. - 8-K, Current Report | - | SEC Filings |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EDITAS MEDICINE | 1,536 | +0,03 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| SOL GLOBAL INVESTMENTS | 0,060 | -5,35 % | SOL Global Investments Corp.: SOL Global Announces Settlement of Outstanding Debentures | Toronto, Ontario--(Newsfile Corp. - January 21, 2026) - SOL Global Investments Corp. (CSE: SOL) (OTCID: SOLCD) (FSE: 9SB0) ("SOL" or the "Company") is pleased to announce that it has satisfied its... ► Artikel lesen | |
| TRINITY BIOTECH | 0,786 | +11,14 % | Trinity Biotech plc: Trinity Biotech Announces Agreements to Strengthen Capital Structure and Support Growth Initiatives | - Arrangements provide increased near-term funding and extend maturity of credit agreement to early 2027 - Equity settlement mechanisms also agreed for milestone payments and contingent acquisition... ► Artikel lesen | |
| FATE THERAPEUTICS | 0,928 | -3,35 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | ||
| ARCTURUS THERAPEUTICS | 7,560 | +7,69 % | Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis Program | ARCT-032 generally safe and well tolerated
Meaningful trends of clinical activity observed via high resolution CT scans
After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class... ► Artikel lesen | |
| OVID THERAPEUTICS | 1,290 | -3,73 % | Ovid Therapeutics Inc.: Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer | NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need,... ► Artikel lesen | |
| CABALETTA BIO | 2,505 | +7,51 % | Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 | ||
| GENERATION BIO | 5,370 | -6,45 % | XOMA Royalty Corporation Enters into Agreement to Acquire Generation Bio Co. | - Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio's collaboration with Moderna - - Generation Bio's cell-targeted lipid nanoparticles (ctLNP) delivery... ► Artikel lesen | |
| LONGEVERON | 0,513 | +0,39 % | Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program | ||
| VOR BIOPHARMA | 13,190 | +9,28 % | Vor Biopharma: Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Multiple Late-Stage Data Readouts Reinforce Telitacicept's Broad Potential Across Autoimmune DiseasesExpansion of Executive Leadership and Board Strengthens Global Development Capabilities Expected... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 319,57 | +4,56 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| QIAGEN | 43,170 | -0,70 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Umsatz und Ergebnis des vierten Quartals hätten die Erwartungen... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,90 | +0,11 % | Avidity Biosciences, Inc. - 8-K, Current Report | ||
| TARSUS PHARMACEUTICALS | 64,62 | +4,24 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,990 | +8,23 % | H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock |
BOLT PROJECTS HOLDINGS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -27,01 % bei einem Aktienkurs von 0,583 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BOLT PROJECTS HOLDINGS INC finden Sie auf Wallstreet Online.